Request a Premium Quote Breaking News TCR2 Therapeutics, BMS to Study Gavo-Cel, Opdivo, Yervoy Combos in Mesothelin-Expressing Cancers Cedilla Therapeutics Raises $82.6M in Series B Financing Hummingbird Bioscience, Merck to Study HMBD-002 With Keytruda in Various Solid Tumors Daiichi Sankyo, AstraZeneca, Merck Partner on Phase III Trial of TROP2, PD-1 Inhibitor Combo In Brief This Week:Â Alphageneron, Deep Lens, TCR2Â Therapeutics, Viome Life Sciences, GlaxoSmithKline European Commission Approves Merck's Keytruda-Chemo Combination for Advanced TNBC Patients
